{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:14:21Z","timestamp":1783577661632,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102641","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:46:25Z","timestamp":1755553585000},"page":"102641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Checkpoint agonists \u2014 immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis"],"prefix":"10.1016","volume":"96","author":[{"given":"Angel Ray","family":"Baroz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra K","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Maverakis","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti K","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-6528","authenticated-orcid":false,"given":"Siba P","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102641_sbref1","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216658","article-title":"Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells","volume":"81","author":"Raychaudhuri","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102641_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult-onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.coi.2025.102641_sbref3","article-title":"Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency","volume":"221","author":"Johnson","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102641_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2025.102641_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib6","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib7","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coi.2025.102641_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00011-023-01742-y","article-title":"From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases","volume":"72","author":"Zhou","year":"2023","journal-title":"Inflamm Res"},{"key":"10.1016\/j.coi.2025.102641_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12738","article-title":"Monoclonal antibody against human Tim-3 enhances antiviral immune response","volume":"89","author":"Li","year":"2019","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib12","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.coi.2025.102641_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coi.2025.102641_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","article-title":"Immune checkpoint inhibitor combinations\u00a0\u2014\u00a0current and emerging strategies","volume":"128","author":"Walsh","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coi.2025.102641_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.coi.2025.102641_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102641_bib17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.coi.2025.102641_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.5114\/ada.2021.112274","article-title":"PD1\/PD-L1 pathway in psoriasis and psoriatic arthritis: a review","volume":"38","author":"Adamczyk","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.coi.2025.102641_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/cei.13646","article-title":"CD4+ LAG-3+ T cells are decreased in active psoriatic arthritis patients and their restoration in vitro is mediated by TNF inhibitors","volume":"206","author":"Gertel","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib20","article-title":"Investigation of the PD-1\/PD-L1 expression in the lesional skins of patients with psoriasis","volume":"13","author":"Emre","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.coi.2025.102641_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/medicina60030373","article-title":"Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice","volume":"60","author":"Popa","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.coi.2025.102641_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102641_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2025.102641_bib24","article-title":"Immune-checkpoint protein VISTA critically regulates the IL-23\/IL-17 inflammatory axis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102641_bib25","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1007\/s10565-023-09833-6","article-title":"Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-\u03baB pathway","volume":"39","author":"Yang","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.coi.2025.102641_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.767868","article-title":"Fibrinogen-like protein 1 serves as an anti-inflammatory agent for collagen-induced arthritis therapy in mice","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.911919","article-title":"TIGIT as a promising therapeutic target in autoimmune diseases","volume":"13","author":"Yue","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib28","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.1700407","article-title":"Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity","volume":"200","author":"Dixon","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-023-04874-3","article-title":"Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells","volume":"6","author":"Kojima","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.coi.2025.102641_bib30","article-title":"The landscape of TIGIT target and clinical application in diseases","volume":"1","author":"Rui","year":"2022","journal-title":"MedComm Oncol"},{"key":"10.1016\/j.coi.2025.102641_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102641_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2025.102641_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4947","article-title":"Anti\u2013PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases","volume":"8","author":"Suzuki","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2025.102641_sbref34","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.jid.2022.06.006","article-title":"The role of PD-L1 on Langerhans cells in the regulation of psoriasis","volume":"142","author":"Tanaka","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102641_sbref35","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jaci.2015.11.021","article-title":"Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells","volume":"137","author":"Kim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102641_bib36","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102641_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/eji.201847862","article-title":"High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis","volume":"49","author":"Fuchs","year":"2019","journal-title":"Eur J Immunol"},{"issue":"Supplement_1","key":"10.1016\/j.coi.2025.102641_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0121","article-title":"DOP81 Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: results from a Phase 1 healthy volunteer clinical trial","volume":"18","author":"Luu","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.coi.2025.102641_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0296","article-title":"P166 optimizing PD-1 agonist signaling with membrane proximal binding of rosnilimab, a clinical stage PD-1 agonist IgG1 antibody","volume":"18","author":"Parmley","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coi.2025.102641_bib40","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1016\/j.coi.2025.102641_bib41","article-title":"Efficacy and safety of neihulizumab (AbGn-168H) in patients with active psoriatic arthritis: 24-week results from a phase II open label study","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102641_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2014.07.003","article-title":"Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis \u2013 xenograft model","volume":"55","author":"Kundu-Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102641_bib43","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2008.38","article-title":"FR255734, a humanized, Fc-silent, anti-CD28 antibody improves psoriasis in the SCID mouse-psoriasis xenograft model","volume":"128","author":"Raychaudhuri","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102641_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102602","article-title":"Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease","volume":"95","author":"Chakraborty","year":"2025","journal-title":"Curr Opin Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:24:27Z","timestamp":1757337867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"alternative-id":["S0952791525001177"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102641","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint agonists \u2014 immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102641"}}